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Background: Hepatitis E virus (HEV) is a major causative agent of acute clinical hepatitis 
in adults throughout much of Asia, the Middle East, and Africa. The lack of an eﬃcient 
cell culture system for HEV has greatly limited our understanding of the mechanisms 
of infection, replication, and pathogenicity of this virus. The yeast two-hybridization 
system is considered to be an eﬃcient method for determining protein-protein interac-
tions and screening interactive proteins associated with host cells.
Objectives: In order to identify the host-cell proteins interacting with the HEV-capsid pro-
teins, a fragment of the HEV-capsid protein p239 (amino acids 368–606) was used as bait; 
human liver cDNA library was used as a source of host-cell proteins, and the screening 
was performed using the CytoTrap yeast two-hybrid system. 
Materials and Methods: The CytoTrap yeast two-hybrid system, which is also called Sos Re-
cruitment System (SRS), was used to analyze the interaction of the p239 fragment with 
host-cell proteins.
Results: We isolated 2 proteins, cytochrome P4502C8 (CYP4502C8) and retinol-binding 
protein 4 (RBP4) after 2 rounds of screening. Co-immunoprecipitation assays showed 
that both the proteins could bind in vitro to the HEV virion in HepG2 cells. 
Conclusions: CYP4502C8 and RBP4 screened from liver cDNA library using the CytoTrap 
yeast two-hybrid system interact with HEV capsid in vitro. 
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1. Background
Hepatitis E virus (HEV), the causative agent of hepati-
tis E, belongs to the family Hepeviridae. At least 4 major 
genotypes of HEV have been recognized; viruses with 
genotypes 1 and 2 are restricted to humans and associ-
ated with epidemics in developing countries, whereas 
those with genotypes 3 and 4 are zoonotic viruses and 
infect humans and several other animals in both devel-
oping and industrialized countries. A new HEV genotype 
was recently detected in a Norway rat in Germany (1). The 
mechanisms of infection, replication, and pathogenesis 
of HEV remain unclear because of the unavailability of a 
suitable tissue culture system  ; identifying the host-cell 
proteins that interact with this virus will help under-
stand these viral mechanisms. The yeast two-hybridiza-
tion system was considered to be an eﬃcient method for 914 HEV-Capsid Protein Interacts With CYP4502C8 and RBP4 Shen Q et al.
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determining protein-protein interactions and screen-
ing interacting proteins from host cells (2, 3). Previous 
studies have shown that homodimers of the truncated 
HEV-capsid proteins E2 (amino acids 394–606) and p239 
(amino acids 368–606) are the dominant antigenic deter-
minants of HEV (4-6). Furthermore, homodimers of p239 
interact to form particles with a 23-nm diameter (5). 
2. Objectives
Therefore, in the current study, we used a fragment of 
p239 as a bait to screen the proteins from the human 
liver cDNA library that interact with the HEV-capsid pro-
tein; the screening was carried out by using the CytoTrap 
yeast two-hybrid system. 
3. Materials and Methods
3.1. Yeast Two-Hybrid System
The CytoTrap yeast two-hybrid system (Stratagene, CA), 
also known as the Sos Recruitment System (SRS), was 
used to screen the proteins from the host cells interact-
ing with the HEV-capsid proteins (7). This system gener-
ates fusion proteins whose interactions in the yeast cyto-
plasm activate the Ras-signaling pathway and induce cell 
growth. This system uses the temperature-sensitive mu-
tant yeast strain cdc25H, which has a point mutation at 
amino acid residue 1328 of the CDC25 gene (8). This mu-
tation prevents the growth of the cdc25H strain at 37°C, 
but allows it to grow normally at room temperature. The 
CytoTrap system is based on the ability of the human Sos 
protein (hSos) to compensate for the defect in the CDC25 
and to activate the Ras-signaling pathway in the yeast. 
Expression of hSos and its subsequent localization to 
the plasma membrane allows the cdc25H yeast strain to 
grow at 37°C. DNA encoding the protein of interest (bait 
protein) is cloned into the multiple cloning site of the 
pSos vector, following which a fusion protein is gener-
ated. Another protein of interest (i.e., the target protein) 
that is expressed as a fusion protein with a myristylation 
sequence is anchored to the plasma membrane. These fu-
sion proteins are coexpressed in the cdc25H yeast strain, 
and the yeast cells are incubated at the restrictive tem-
perature of 37°C. If the bait and target proteins interact 
with each other, hSos is recruited to the membrane, 
thereby activating the Ras-signaling pathway and allow-
ing the cdc25H yeast strain to grow at 37°C.
3.2. Vectors
The fragment of HEV ORF2 coding for aa 394–606 was 
ampliﬁed by RT-PCR; the HEV ORF2 fragment was derived 
from the Chinese HEV strain SH-SW-zs1 (GenBank acces-
sion no. EF570133) with 5′-CAg gat CCC AGT TGT TTT ACT 
CAC GCC-3′ (E2-sense) and 5′-CAg tcg ACC ACA GAA TGA 
GGT GCG AGG-3′ (E2-antisense) (sites of the restriction 
enzymes BamHI and SalI are italicized). The ampliﬁed 
fragment was subcloned into the pSos vector. The recom-
binant Bait-E2 plasmid was sequenced to identify the 
correction. Other control vectors used in the yeast two-
hybrid screening were obtained along with the human 
liver cDNA library (Stratagene, USA).
3.3. Test of the Expression of Bait-E2 in Yeast Cells
Protein expression of the Bait-E2 plasmid in yeast cells 
was analyzed by western blot analysis. Brieﬂy, 5 ml of the 
yeast cell culture transformed by the Bait-E2 plasmid was 
used for protein isolation after 3 days of incubation at 
room temperature. The yeast cells were pelleted by cen-
trifuging the culture at 1000 g for 5 min, and then the 
pellet was resuspended into 200 μl of cell lysis buﬀer 
(140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH-
2PO4, and 1% Triton X-100) containing freshly added pro-
tease inhibitors (1 mM phenymethylsulfonyl ﬂuoride, 10 
μg/ml aprotinin, 1 μM pepstatin A, 100 μM leupeptin, 1 μg/
ml chymostatin). The pellet resuspended in the buﬀer 
was vortexed with an equal volume of acid-washed glass 
beads (diameter, 0.5 mm, Stratagen) for 5 min at 4°C and 
then centrifuged at 12,000 g for 5 minutes. The lysate was 
collected and the supernatant was transferred into clean 
1.5 ml screw-cap tubes. The analysis was performed by the 
standard western blot technique using mouse monoclo-
nal anti-Sos antibody (Upstate, USA). 
3.4. Screening
Before the screening, Bait-E2 was tested for absence of 
autoactivation by cotransforming it with pMyr Lamin 
C plasmid as previously described in the literature (9). 
The screening was performed according to the manufac-
turer’s instructions of CytoTrap yeast two-hybrid system. 
Brieﬂy, cdc25H yeast cells were cotransformed with the 
Bait-E2 plasmid and the cDNA library plasmid. The expres-
sion of the cDNA in the library plasmid was controlled by 
a galactose-inducible promoter. The transformants were 
grown on and selected from minimal-glucose plates and 
incubated for 4 to 6 days at 25°C. Subsequently, the colo-
nies were replica-plated onto minimal-galactose plates 
and incubated at 37°C for 5 to 7 days. Positive colonies 
exhibiting eﬃcient growth on the minimal-galactose 
plates at 37°C were isolated and tested for galactose-de-
pendent growth at 37°C. 
3.5. Isolation of pMyr cDNA Plasmid DNA From Yeast
Positive cDNA plasmids were isolated from yeasts by 
using E.Z.N.A.® Yeast Plasmid Kit (Omega Bio-Tek, USA) 
according to the manufacturer’s instructions. The plas-
mids were transformed into competent DH5α E. coli cells 
and then isolated for sequencing. Similarity searches for 
the sequences were carried out using Basic Local Align-
ment Search Tool (http://www.ncbi.nlm.nih.gov/BLAST/). 
In order to verify the speciﬁcity of the interaction be-
tween the bait and the target proteins, the bait and posi-
tive plasmids were re-transformed into yeast cells and 
then plated onto selective media. The transformants 
were tested for their ability to grow on SD/galactose agar 
plates at 37°C. 915 HEV-Capsid Protein Interacts With CYP4502C8 and RBP4 Shen Q et al.
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3.6. Immunoprecipitation Assays
Immunoprecipitation assays were performed to iden-
tify the interaction of the proteins in vitro. HepG2 cells, 
the permissive cell line for HEV, were maintained and 
cultured in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM, 
Invitrogen, USA) containing 10% fetal bovine serum (FBS). 
These cells were plated on a 100-mm plate and incubated 
for about 2 days to obtain a good monolayer. They were 
then washed with cold phosphate-buﬀered saline (PBS) 
for 3 times, and subsequently, 1 mL of radioimmunopre-
cipitation assay buﬀer was added to the cells. The cell 
lysate was obtained by centrifugation at 15,000 g for 30 
min at 4°C after incubating the cells on ice for 5 minutes 
with periodic mixing. Before immunoprecipitation, 20 
μl of Protein A + G Agarose (Tiangen, China) and 1 μg of 
normal IgG (both obtained from the same species) along 
with the detection antibodies were added to 200 μL of 
the cell lysate to pre-clear the lysate. The lysate was cen-
trifuged at 1000 g for 5 min at 4°C after incubating them 
for 3 h, and the supernatant was transferred to fresh 
tubes. We added 30 μL of Protein A+G Agarose and 0.4 
μg of rabbit polyclonal antibody against recombinant 
human RBP4 (Sino Biological Inc., USA) or anti-HEV poly-
clonal antibody (Millipore, USA) to the lysate. The cell ly-
sate mixture was then incubated overnight with gentle 
shaking at 4°C. The immunoprecipitates were collected 
by centrifuging the cell lysate mixture at 1000 g for 5 
min at 4°C and then washed with 1.5 mL PBS 4 times; they 
were then resolved by sodium dodecyl sulpfate-polyac-
rilamide gel electrophoresis (SDS-PAGE) and detected by 
western blotting. Brieﬂy, the samples were heated at 95°C 
for 5 minutes. After the gel was run, the proteins were 
transferred onto PVDF membranes (Millipore, Japan) by 
using Semi-dry Blotters (Hoefer Inc., USA) at 75 mA for 1 h. 
The membranes were blocked for 30 min by suspending 
them in 1X PBS containing 5% non-fat dry milk and 0.1% 
Tween-20 on a shaker at room temperature; they were 
further incubated overnight in HEV viral suspension at 
4°C. After the membranes were washed 3 times with PBS, 
they were incubated with the secondary antibody (Mil-
lipore, Japan) at a dilution of 1:1000 for 2 h at room tem-
perature. Subsequently, the bound antigen was detected 
by using the 3, 3′, 5, 5′-Tetramethylbenzidine substrate 
(Tiangen Biotech, China). 
4. Results
4.1. Bait-E2 Was Suitable for CytoTrap
After the sequencing, Bait-E2 was transformed into 
cdc25H yeast cells to detect the expression of the plasmid 
by performing western-blot analysis. The results showed 
that the ORF2 E2 fragment of HEV can fuse with the gene 
encoding hSos, following which this protein could be 
expressed (Figure 1), and that cdc25H yeast cells cotrans-
formed with the positive plasmid pMyr Lamin C cannot 
grow in either SD (–UL)/Glucose or SD (–UL) Galactose me-
dia, which indicates that the bait plasmid does not show 
auto-activation. 
4.2. Yeast Two-Hybrid Screening
We identiﬁed 3 positive clones from the human liver 
cDNA library after 2 rounds of screening; 2 of these 3 
clones had the same nucleotide sequence, and thus, we 
identiﬁed 2 distinct sequences. Similarity searches for 
these 2 sequences indicated that one shared 100% nu-
cleic acid identity with the gene encoding human cyto-
chrome P4502C8 (CYP4502C8) and the other shared 100% 
nucleic acid identity with the gene encoding Homo sa-
piens retinol binding protein 4 (RBP4). To eliminate the 
Figure 1. Analysis of the Expression of Bait-E2 in Yeast Cells by the West-
ern Blot Method
Lane 1, yeast cells transformed with bait-e2; lane 2, yeast cells transformed 
with the pSos vector.
Figure 2. Immunoprecipitation and Western-Blot Assay for Detection of 
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chance of a false-positive clone and to identify the reac-
tions, each of those 2 plasmids was recotransformed into 
cdc25H yeast cells together with Bait-E2. We observed 
that both of the yeast cells grew in SD/glu (–UL) agar plate 
at 25°C and SD/gal (–UL) at 37°C, but did not grow in SD/
glu (–UL) at 37°C, which indicates that the 2 proteins in-
teracted with the HEV-capsid fragment. The immunopre-
cipitation assays showed that both CYP4502C8 and RBP4 
had immunoprecipitation reactions with HEV virion in 
HepG2 cells (Figure 2).
5. Discussion 
Hepatitis E is a major public health disease in many de-
veloping countries of Asia and Africa, and it also occurs 
sporadically in some industrialized countries (10-12). 
HEV is known to be a zoonotic virus, and some of its gen-
otypes (genotype 3 and 4) are transmitted freely between 
swine and humans in some developing and developed 
countries (13-15). However, the lack of an eﬃcient cell-
culture system for HEV greatly hampers detailed analysis 
of the replication cycle of the virus in infected cells, be-
cause of which many important questions are diﬃcult to 
resolve (16). Understanding the interactions between the 
virus and proteins from host cells are eﬃcient ways to 
analyze viral infection, replication, and other processes 
associated with infection by this virus. The yeast two-hy-
bridization system is considered as an eﬃcient method 
for screening interactive proteins involved in the patho-
genesis of HEV. 
We isolated 2 proteins, CYP4502C8 and RBP4, after per-
forming 2 rounds of screening. Both the proteins were 
further analyzed by the immunoprecipitation assay, 
and they were found to interact with the HEV virion. The 
CYP450 superfamily is a large and diverse group of en-
zymes. The function of most CYP enzymes is to catalyze 
the oxidation of organic substances. Research indicates 
that the HEV-capsid protein interacts with CYP2A6 and 
decreases its coumarin 7-hydroxylation activity (17). 
Previous studies indicate that the expression of CYP2A6 
markedly increases in hepatocytes immediately adjacent 
to areas of ﬁbrosis and inﬂammation in sections of liver 
infected with HBV or hepatitis C virus (HCV), and that it 
is impaired in acute hepatitis A infection (18, 19). Recent 
investigations have shown that apart from viral factors, 
CYP2E1 polymorphism might be associated with the in-
creased risk of liver diseases, including that by HEV in 
northeast India (20). In the current study, HEV-capsid 
proteins interacted with CYP4502C8, an isoenzyme of 
CYP2A6 and CYP2E1. Taken together, the results suggest 
that various human cytochrome P450 isoforms probably 
are closely related to HEV. Therefore, we conclude that 
HEV may infect host cells by interacting with the cyto-
chrome P450 family proteins and result in the activation 
of these enzymes. However, further extensive research is 
required to identify if and how the virus aﬀects the en-
zyme activities.
Retinol-binding protein 4 (RBP4) is the only speciﬁc 
transport protein for the circulation of retinol (vitamin 
A), and its main function is thought to be the delivery 
of retinol to tissues (21). Studies have shown that serum 
RBP4 level is correlated with hepatocellular injury in pa-
tients with nonalcoholic fatty liver disease (NAFLD), and 
that it is also a new marker for virus-induced steatosis 
in patients infected with HCV having genotype 1 (22, 23). 
Recently, Kwon et al found that the level of serum RBP4 
determines disease severity in patients with chronic liver 
disease (24). However, thus far, the relationship between 
hepatitis E and RBP4 remains unknown, and the relation-
ship between HEV and RBP4 and the eﬀect of this interac-
tion on disease severity is unclear. 
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